The role of RBCs in hemostasis and thrombosis is complex. While RBCs are directly involved in increasing thrombin generation and platelet activation, they are also indirectly involved in affecting platelet margination and altering blood viscosity. Therefore, it is often difficult to determine the relative contributions of these different mechanisms to hemostasis and thrombosis.
RBCs express the Fas ligand FasL, and the death receptor FasR (1) . Activation of FasR on RBCs leads to a loss of membrane asymmetry and exposure of negatively charged phospholipids, such as phosphatidylserine (PS), on the cell surface. PS provides an "eat me" signal that directs the removal of aged RBCs from the circulation. Indeed, aged RBCs have higher levels of surface PS compared with young RBCs. Platelets express FasL and induce apoptosis of neural cells and apoptosis in a stroke model (2) .
In the current issue of the JCI, Klatt et al. (3) present the interesting observation that platelets induce PS exposure on RBCs via an interaction between FasL on platelets and FasR on RBCs. Although ADP stimulation of platelets has been shown to increase surface expression of FasL (2), Klatt et al. (3) found no effect on RBC PS exposure after inhibition of platelet activation with clopidogrel, an inhibitor of ADP signaling via the ADP receptor P2Y 12 .
The presence of PS and other negatively charged phospholipids on cell surfaces facilitates the assembly of coagulation factor complexes by binding to the γ-carboxyglutamic acid residue-rich domain present in various coagulation factors (4 
RBCs and hemostasis
Recent studies have shown that thrombosis can be distinguished from hemostasis. For instance, factor XII contributes to thrombosis but has no role in hemostasis (9) . Hemostatic plugs contain a core of densely packed, highly activated platelets covered by a shell of loosely packed, less activated platelets (10) . Few RBCs are present in hemostatic plugs, suggesting that they contribute to hemostasis indirectly. This may occur by increasing platelet margination towards the wall of the injured vessel or by biochemical activation of resident platelets ( Figure 1A ).
Anemia is associated with increased bleeding. An early study found that transfusion of RBCs into patients with severe anemia and normal platelet counts corrects the bleeding time (11) . RBC transfusion also shortens the bleeding time in anemic and thrombocytopenic rabbits (12) . Klatt et al. (3) found that anemic mice (21%-28% hematocrit) had prolonged bleeding in a tail transection model compared with normal mice (hematocrit 35%-45%), whereas an increase in hematocrit (>50%) did not affect bleeding. Similarly, Walton et al. (8) found that mice with an increased hematocrit (~47%) had a normal tail bleeding time.
RBCs and thrombosis
Arterial thrombi are platelet-rich (socalled "white clots") and typically form after rupture of atherosclerotic plaques (ref. 13 and Figure 1B) . Platelets provide the cellular component to these thrombi RBCs are the most abundant circulating cells in humans and typically comprise 35% to 45% of the blood volume (hematocrit). Anemia is associated with an increase in bleeding, and epidemiological studies have shown an association between an elevated hematocrit and thrombosis. RBCs may contribute to hemostasis and thrombosis via mechanisms that include platelet margination leading to an increase in the near-wall platelet concentration, blood viscosity, thrombin generation, and platelet activation. In this issue of the JCI, Klatt et 
RBCs in venous clots during plateletmediated clot retraction (15).
Several epidemiological studies have examined the associations between elevated hematocrit and both arterial and venous thrombosis (16) . One study reported that patients with a high hematocrit had a 1.5-fold increased risk of venous thromboembolism compared with patients with a low hematocrit (17) . Another study found that perioperative RBC transfusion was associated with venous thromboembolism (18) .
The ferric chloride carotid artery thrombosis model is the most commonly used mouse model of thrombosis (19) . Importantly, one study showed that in this model, RBCs are the first cells to adhere to the damaged endothelium, recruit platelets, and form nuclei for the formation of large platelet complexes that ultimately occlude blood flow (20) . Of note, a platelet-rich thrombus is formed in this model with very few RBCs incorporated as islands (ref. 13 and Figure 1B) . Klatt et al. (3) found that anemic mice exhibited a prolonged occlusion time in the ferric chloride carotid artery thrombosis model (15% ferric chloride for 3 minutes) but the occlusion time was not affected by an increased hematocrit. In contrast, Walton et al. (8) used a similar thrombosis model (10% ferric chloride for 2 minutes) and observed a significant shortening of the occlusion time in mice with a high hematocrit. Use of a less severe model may explain why Walton et al. (8) observed an effect of high hematocrit on thrombosis. The two studies conclude that hematocrit influences platelet adhesion and aggregate clots") and form in-valve pockets on an intact endothelium under low shear (ref. 14 and Figure 1C ). Human venous thrombi consist of a "red" part enriched in RBCs and fibrin and a "white" part enriched in platelets (14) . Since RBCs comprise approximately 50% of the mass of venous thrombi, they may contribute to thrombin generation in this scenario. Interestingly, crosslinking of fibrin is required to retain formation at the injured vessel (3), and that RBCs promote arterial thrombosis via a platelet-dependent increase in thrombus growth (8) 
